Press Releases InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies October 24, 2023 Read More » InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update September 29, 2023 Read More » InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance September 22, 2023 Read More » InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference September 7, 2023 Read More » InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET July 21, 2023 Read More » InMed Provides Update on BayMedica Rare Cannabinoid Business July 20, 2023 Read More » InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa June 22, 2023 Read More » InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting June 1, 2023 Read More » InMed to Participate in Upcoming Virtual Investor Events May 24, 2023 Read More » InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET May 18, 2023 Read More » InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update May 15, 2023 Read More » InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa March 28, 2023 Read More » InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions March 13, 2023 Read More » InMed to Participate in Upcoming Investor Events March 7, 2023 Read More » InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update February 17, 2023 Read More » InMed Submits Form 12b-25 February 9, 2023 Read More » InMed Provides Business Update and Milestones for 2023 January 10, 2023 Read More » InMed Announces Results of 2022 Annual General Meeting December 15, 2022 Read More » InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor December 12, 2022 Read More » InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market November 21, 2022 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Next » Management Learn More Board of Directors Learn More Scientific Advisory Board Learn More Investor Alerts Sign up to receive news releases from InMed Pharmaceuticals. SIGN UP
InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies October 24, 2023 Read More »
InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update September 29, 2023 Read More »
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance September 22, 2023 Read More »
InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference September 7, 2023 Read More »
InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET July 21, 2023 Read More »
InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa June 22, 2023 Read More »
InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting June 1, 2023 Read More »
InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET May 18, 2023 Read More »
InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update May 15, 2023 Read More »
InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa March 28, 2023 Read More »
InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions March 13, 2023 Read More »
InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update February 17, 2023 Read More »
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor December 12, 2022 Read More »
InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market November 21, 2022 Read More »